Search

Displaying results 2491 - 2500 of 4301 in total
  1. Drug

    Lutetium Lu 177 dotatate

    go.drugbank.com/drugs/DB13985
    ApprovedInvestigational

    Lutetium Lu 177 dotatate was approved by the FDA as Lutathera in January 2018 for intravenous injection. … emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by

  2. Drug

    Copper histidinate

    go.drugbank.com/drugs/DB32041
    Approved

    It was approved by the US FDA in January 2026 for the treatment of pediatric patients with Menkes disease.[L54993,L54998] … Menkes disease is a rare, X-linked recessive disorder caused by pathogenic variants in the ATP7A gene, which encodes a copper transport protein essential for absorbing dietary copper and transporting it

  3. Drug

    R-30490

    go.drugbank.com/drugs/DB09179
    Experimental

    R-30490 was found to be the most selective agonist for the mu opioid receptor out of all the fentanyl analogues tested, but it has never been introduced for medical use in humans, although the closely … It was first synthesized by Janssen Pharmaceutica as part of a structure-activity relationship study of fentanly and its derivatives.

  4. Drug

    H3B-8800

    go.drugbank.com/drugs/DB14017
    Investigational

    H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine [L2551]. … H3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551].

  5. Drug

    Acarbose

    go.drugbank.com/drugs/DB00284
    ApprovedInvestigational

    [L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels.

  6. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as fibrinolysin - as part of the fibrinolytic pathway that breaks down fibrin blood clots. This pathway is activated when a clot is no longer need...

  7. Drug

    Stannsoporfin

    go.drugbank.com/drugs/DB04912
    Investigational

    Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing

  8. Drug

    Irofulven

    go.drugbank.com/drugs/DB05786
    Investigational

    ” status by the U.S. … MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis.

  9. Drug

    Poliovirus type 2 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10796
    ApprovedInvestigational

    Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by

  10. Drug

    Smallpox (Vaccinia) Vaccine, Live

    go.drugbank.com/drugs/DB14711
    ApprovedInvestigational

    [L12747] ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain.